MarginsXMarginsX
Home › Markets › Health Care › ADPT

Adaptive Biotechnologies Corporation (ADPT)

ADPT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$27.87
-4.03% on the day
Market cap
$4.5B
Mid cap
Revenue · 2025
$277.0M
+54.8% on 2024
Net income · 2025
-$59.5M
-21.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1478320/000119312526076902/0001193125-26-076902-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerADPT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2019
SEC CIK0001478320
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inWA

Financials · 2025

LineValue
Revenue$277.0M
Net income-$59.5M
Operating income-$57.1M
Net margin-21.5%
Operating margin-20.6%
Revenue growth+54.8%
Cash$70.5M
Total assets$512.7M
P/E (computed)Net income was not positive
P/S (computed)16.3×

Warning signs

Cash runway
212.2 months
$75.6M cash at September 30, 2026
Share count, 1 year
+6.0%
2025-10-31 to 2026-10-30 · +11.8% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$117.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$75.6M cash; operating cash flow -$1.1M a quarter.Report 2026-09-30
Shares outstanding161,876,694 (2026-10-30); 152,665,188 a year earlier; 144,772,751 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Seattle, Washington, United StatesPCAOB Form AP 2026-03-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $117.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$83.9M$2.9M$9.6M$75.6M$0$298.0M10-Q 2026-11-04
Q2 2026
2026-06-30
$71.6M-$39.8M-$6.4M$169.9M$0$308.1M10-Q 2026-08-04
Q1 2026
2026-03-31
$70.9M-$20.0M-$9.5M$77.6M$130.6M$295.4M10-Q 2026-05-05
Q4 2025
2025-12-31
$71.7M-$13.6M$2.1M$70.5M$131.2M$277.0M10-K 2026-02-26
Q3 2025
2025-09-30
$94.0M$9.5M-$7.1M$55.0M$131.8M$252.8M10-Q 2026-11-04
Q2 2025
2025-06-30
$58.9M-$25.6M-$12.4M$43.2M$133.6M$205.2M10-Q 2026-08-04
Q1 2025
2025-03-31
$52.4M-$29.9M-$28.5M$50.6M$133.6M$189.5M10-Q 2026-05-05
Q4 2024
2024-12-31
$47.5M-$33.7M-$12.5M$47.9M$133.3M$179.0M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B72020-08-21
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 839 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.8%
1 month+14.9%
3 months+18.7%
Year to date+78.8%
1 year+105.4%
From 52-week high-4.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CRSPCRISPR Therapeutics AG Common Shares$40.37-4.43%$3.9B
TARSTarsus Pharmaceuticals Inc.$78.68-1.99%$3.9B
RLAYRelay Therapeutics Inc.$17.27-4.53%$3.8B
SRRKScholar Rock Holding Corporation$44.54+3.09%$5.4B
IOVAIovance Biotherapeutics Inc.$7.55-2.71%$3.5B
IBRXImmunityBio Inc.$5.98-0.66%$6.4B
KODKodiak Sciences Inc$100.73-9.41%$6.6B
ADMAADMA Biologics Inc$13.47-1.54%$3.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier